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Abstract
Background: Futile reperfusion (poor functional status despite successful reperfusion) was observed in up to 67%
of patients enrolled in recent endovascular treatment (EVT) clinical trials. We investigated the impact of baseline
stroke severity on both futile reperfusion and therapeutic benefit of successful EVT.
Methods: Using a prospective multicenter stroke registry, we identified consecutive ischemic stroke patients with
anterior circulation large artery occlusion, who were reperfused successfully by EVT (Thrombolysis in Cerebral Infarction
grade 2b–3). The rate of futile reperfusion was assessed across the initial National Institutes of Health Stroke Scale
(NIHSS) scores. The frequency of poor outcomes (modified Rankin scale [mRS] 3–6) according to NIHSS scores was
compared between patients revascularized successfully by EVT and those who did not receive EVT, after standardizing
for age.
Results: Among 21,591 patients with ischemic stroke, 972 (4.5%) received EVT within 12 h of onset, including 440 who
met study eligibility criteria. Futile reperfusion was observed in 226 of the 440 study-eligible patients (51.4%) and was
associated with stroke severity: 20.9% in NIHSS scores ≤5, 34.6% in 6–10, 58.9% in 11–20, and 63.8% in > 20 (p < 0.001).
Nonetheless, the therapeutic benefit of EVT also increased with increasing stroke severity (p for interaction < 0.001): 0.
1% in NIHSS ≤5, 18.6% in 6–10, 28.7% in 11–20, and 34.3% in > 20.
Conclusions: EVT is more beneficial with increasing stroke severity, although futile reperfusion also increases with
higher stroke severity.
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Background
Futile reperfusion, defined as poor 3-month outcome
(modified Rankin Scale, mRS ≥3) despite successful re-
perfusion (Thrombolysis in Cerebral Infarction [TICI]
grade 2b to 3 reperfusion flow after endovascular treat-
ment [EVT]) [1–3], ranged from 29 to 67% in the five
pivotal EVT clinical trials published in 2015 [4–8]. Earl-
ier studies suggested that initial stroke severity, as mea-
sured by the National Institutes of Health Stroke Scale
(NIHSS), strongly predicts futile reperfusion [1, 9, 10]; in
a pooled analysis, 66% of patients with initial NIHSS
scores ≥20 were functionally dependent despite success-
ful revascularization [2].
At the same time, a recent analysis [11], pooling Inter-
ventional Management of Stroke III [12] and MR
CLEAN data [5], suggested that EVT might be most
beneficial in severe stroke patients (NIHSS ≥20). An-
other pooled analysis [13] of the five 2015 EVT trials
(MR CLEAN [5], ESCAPE [4], REVASCAT [8], SWIFT
PRIME [7], and EXTEND IA [6]) reported that EVT was
similarly effective across the whole range of NIHSS
scores; the adjusted odds ratio (OR) was 2.52 (confi-
dence intervals [CIs], 1.40–4.54) in patients with NIHSS
scores ≥21, and 1.67 (CI 0.80–3.50) for NIHSS ≤10 (p
for interaction = 0.45).
Futile reperfusion is a useful concept that limits study
subjects to those treated successfully with EVT. It thereby
leaves aside factors related to reperfusion failure related to
operators, such as experience levels and diversity of tech-
niques [14]. The clinician can then consider individual
patient factors that influence outcome after reperfusion.
This concept is most valuable for observational or
quasi-experimental studies examining outcomes in
heterogeneous, real-world settings.
Using a nationwide multicenter stroke registry data-
base [14, 15], this study aimed to investigate whether
futile reperfusion depends on initial NIHSS scores, and
to estimate the therapeutic benefit of EVT across NIHSS
scores by comparing those treated successfully with EVT
to those not treated with EVT.
Methods
Study subjects
We retrospectively analyzed the Clinical Research Center
for Stroke-5th division (CRCS-5) registry, a prospective,
nationwide, multicenter, acute stroke database established
in 2008 [14, 15]. The study group consisted of 14
academic and regional stroke centers. In the registry, we
identified consecutive acute ischemic stroke patients with-
out pre-stroke disability (mRS was 0 to 1), who had anter-
ior circulation large artery (middle cerebral artery [MCA]
including M1 and M2, or internal carotid artery [ICA])
occlusion, and who were treated successfully with EVT
(TICI grade 2b or 3) within 12 h of stroke onset, between
November 2009 and July 2014 (defined as the successful
EVT group). We evaluated determinants of futile reperfu-
sion in this group. We also identified acute ischemic
stroke patients presenting with MCA or ICA occlusions
within 12 h of onset but who were not treated with EVT
(defined as the no-EVT group). We estimated therapeutic
benefits of EVT across the whole range of NIHSS scores,
comparing the successful EVT and no-EVT groups, with
direct standardization for age.
Data collection and parameter definitions
From the registry database, we obtained demographics,
stroke risk factors and medical history, stroke characteris-
tics and treatments (initial NIHSS scores, pre-stroke mRS,
ischemic stroke subtype according to the Trial of Org
10,172 in Acute Stroke Treatment (TOAST) criteria, with
some modifications [16], preceding intravenous thromb-
olysis, and intervals from onset to initiating EVT, as well
as laboratory data and large vessel status. Additionally,
post-EVT vessel status was graded centrally, using the
TICI grade, by three experienced vascular neurologists,
who reviewed angiographic images (Lee J, Hong J-H, and
Park H-K, kappa index = 0.85).
The primary outcome measure was the proportion of
futile reperfusion, defined as a 3-month mRS score of 3 to
6 despite successful reperfusion (TICI grade 2b or 3),
according to initial NIHSS scores, categorized as ≤5, 6–10,
11–20, and > 20 in the EVT group [2, 10]. The secondary
outcome measure was the predicted therapeutic benefit
for each NIHSS category, which was estimated as the
difference between the proportion of patients with mRS
scores of 3 to 6 who were treated successfully with EVT
(the successful EVT group), and the age-standardized
proportion of patients with mRS scores of 3 to 6 not
treated with EVT (the no-EVT group).
Statistical analysis
Summary statistics were presented as the number of
subjects (percentage), for categorical variables, and as
mean ± SD or median (interquartile range), for continuous
variables. Group comparisons were made using Pearson’s
chi-squared test for categorical variables and Student’s
t-test or the Mann-Whitney U test for continuous
variables, where appropriate.
Comparisons of clinical and laboratory profiles were
made according to futile reperfusion status in the EVT
group, and the proportion of futile reperfusion according
to each initial NIHSS category was also presented. A lin-
ear trend between futile reperfusion and initial NIHSS
category was examined with a chi-squared test for trend.
To estimate the therapeutic benefit of EVT according
to each NIHSS category and to remove the influence of
age, we standardized the age distribution of the no-EVT
group (a surrogate control group) to the successful EVT
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group. Following this step, a simple weighted linear re-
gression model was used to test a trend of linearity of
the odds of EVT for patients with mRS scores of 0–2
compared to those with scores of mRS 3–6, according to
initial NIHSS categories classified into 0–5, 6–10, 11–
20, and > 20. See Additional file 1: Appendix for details.
As a post hoc analysis, we also assessed the thera-
peutic benefits of EVT regardless of reperfusion status.
All patients who received EVT were defined as the whole
EVT group and the therapeutic benefit of EVT according
to each NIHSS category in this population was esti-
mated, using the same standardization method and sim-
ple weighted linear regression model. Additionally, the
proportions of futile reperfusion and the effect of NIHSS
on futile reperfusion were obtained and compared be-
tween patients less than 80 years and 80 years or greater,
in the successful EVT group.
Also, as a sensitivity analysis, we analyzed the propor-
tions of futile reperfusion in patients successfully treated
with EVT within 6 h of onset, and the therapeutic bene-
fit of EVT according to each initial NIHSS category,
comparing patients treated successfully with EVT within
6 h of onset and those not treated with EVT despite pre-
senting within 6 h of onset.
To explore predictors of futile reperfusion, we ana-
lyzed the successful EVT group using binary logistic re-
gression models with futile reperfusion as an outcome
variable. Unadjusted and adjusted ORs and 95% CIs of
potential predictors were estimated.
Results
Among 21,591 consecutive patients, hospitalized with acute
ischemic stroke over a span of 57months, 972 (4.5%) re-
ceived EVT within 12 h of stroke onset. Of those 972 pa-
tients, 533 (54.8%) were recanalized successfully with EVT
(TICI grade 2b or 3), and of those 533 patients, 440 pa-
tients with anterior circulation large artery occlusion were
included in the successful EVT group (male, 58%; age, 67.3
± 12.3 years; onset to EVT time, 4.19 ± 1.96 h) (Additional
file 2: Figure S1). In the successful EVT group, the overall
rate of futile reperfusion (3-month mRS score of 3 to 6)
was 51.4% (n = 226). Compared to those without futile re-
perfusion, those with futile reperfusion were more likely to
be female, hypertensive, have higher creatinine levels,
higher NIHSS scores, were less likely to be current smokers
(all p values < 0.05; Table 1), and tended to be older (p =
0.08). Onset to start of EVT (i.e., arterial puncture) and the
location of lesions were not associated with futile reperfu-
sion. Symptomatic hemorrhagic transformation and neuro-
logic progression (mostly attributable to swelling of
infarcted brain or perilesional edema) were more common
in patients with futile reperfusion (symptomatic
hemorrhagic transformation; 8.8% vs. 2.8%, neurologic pro-
gression; 17.7% vs. 10.3%, p’-values < 0.001).
Futile reperfusion rates increased as initial NIHSS
scores increased (p for trend < 0.001, Fig. 1); futile reper-
fusion was seen in 21% of patients with NIHSS ≤5 com-
pared to 64% with NIHSS > 20.
However, the predicted therapeutic benefits of EVT also
increased as initial NIHSS scores increased (Fig. 2a; p =
0.04 for the linear trend test of ORs). Patients with NIHSS
scores ≤5 experienced the lowest likelihood of therapeutic
benefit from EVT (0.1%), while those with NIHSS scores
> 20 experienced the highest likelihood of benefit (34%).
The methods for age-specific direct standardization are
detailed in Additional file 3: Table S1.
Multivariable analysis showed that, among patients
with successful reperfusion, older age and higher initial
NIHSS scores increased the chance of futility, while
pre-stroke antithrombotic medications decreased it
(Table 2). Time from onset of stroke to start of EVT was
not associated with futile reperfusion. Time to reperfu-
sion data were not available.
As a post hoc analysis, of those 972 patients who re-
ceived EVT, 784 (80.7%) with anterior circulation large
artery occlusion were analyzed regardless of reperfusion
status as the whole EVT group (Additional file 2: Figure
S1). This post hoc analysis revealed that the predicted
therapeutic benefits of EVT also increased with the in-
crease of the initial NIHSS score (Fig. 2b). The OR for
favorable outcomes significantly increased as initial
stroke severity increased (p = 0.02 for the linear trend
test of ORs). The methods for age-specific direct
standardization in this group are also detailed in Add-
itional file 4: Table S2. An additional post hoc analysis
with age stratification in the successful EVT group
showed that futile reperfusion was more common in
patients aged 80 years or more, compared to patients
aged less than 80 years (22.1% versus 5.1%, p < 0.001,
Additional file 5: Figure S2) but the impact of NIHSS on
futile recanalization seemed to be similar between both
age groups, although the increase of futile recanalization
rates with increasing NIHSS scores lost statistical signifi-
cance in those patients aged 80 or more (Additional file
6: Figure S3).
Sensitivity analyses of patients treated with EVT
within 6 h of onset showed that the futile reperfusion
rate also increased with increasing NIHSS scores (p for
trend < 0.001, Additional file 7: Figure S4). In fact, pa-
tients with the lowest NIHSS scores (NIHSS≤5) showed
negative therapeutic benefits of EVT (Additional file 8:
Figure S5). The predicted therapeutic benefits of EVT
also showed a trend towards increasing as NIHSS scores
increased (p = 0.051 for the linear trend test of ORs).
Discussion
Our study results suggest that the therapeutic benefits
of EVT increase with an increase in stroke severity,
Lee et al. BMC Neurology           (2019) 19:11 Page 3 of 9
Table 1 Comparison of the futile reperfusion group and the no-futile reperfusion group after successful reperfusion
Futile reperfusion (3-month mRS 3–6
with TICI grade 2b–3) n = 226
No-futile reperfusion (3-month mRS 0–2
with TICI grade 2b–3) n = 214
P-value
Age, mean ± SD 70.3 ± 12.1 64.0 ± 11.8 0.08d
Male, % 120 (53.1) 135 (63.1) 0.04a
TOAST 0.96a
LAA 51 (22.6) 50 (23.4)
CE 131 (58.0) 121 (56.5)
others 44 (19.5) 43 (20.1)
Hypertension, % 151 (66.8) 122 (57.0) 0.04a
Diabetes mellitus, % 58 (25.7) 42 (19.6) 0.14a
Hyperlipidemia, % 46 (20.4) 47 (22.0) 0.73a
Current Smoking, % 37 (16.4) 62 (29.0) 0.002a
Atrial fibrillation, % 120 (53.1) 108 (50.5) 0.63a
NIHSS, IQR 16 (12–19) 12 (8–17) < 0.001c
NIHSS ≤5 9 (4.0) 34 (15.9) < 0.001a
NIHSS 6~10 28 (12.4) 53 (24.8)
NIHSS 11~20 152 (67.3) 106 (49.5)
NIHSS > 20 37 (16.4) 21 (9.8)
Pre-stroke antithrombotics, % 83 (36.7) 93 (43.5) 0.17a
Pre-stroke statin, % 46 (20.4) 46 (21.5) 0.82a
SBP, mean ± SD 143.7 ± 27.3 138.4 ± 27.0 0.92d
Creatinine, mg/dL, mean ± SD 0.97 ± 0.48 0.92 ± 0.28 0.02d
Total cholesterol, mg/dL, mean ± SD 165.4 ± 39.7 166.1 ± 40.6 0.84d
Initial random glucose,
mg/dL, mean ± SD
139.5 ± 49.2 130.0 ± 41.5 0.20d
Preceding IVT, % 154 (68.1) 154 (72.0) 0.41a
Onset to EVT start time, min, mean ± SD 257.4 ± 110.9 245.3 ± 124.0 0.18d
Location of occlusion, % 0.66a
MCA 119 (52.7) 122 (57.0)
ICA 56 (24.8) 49 (22.9)
MCA + ICA 51 (22.6) 43 (20.1)
Location of lesions, %
Right hemisphere 110 (48.7) 110 (51.4) 0.64a
Left hemisphere 111 (49.1) 97 (45.3)
Both hemisphere 5 (2.2) 7 (3.3)
Symptomatic HT 20 (8.8) 6 (2.8) < 0.001b
Neurologic progression* 40 (17.7) 22 (10.3) < 0.001b
* Neurologic progression was defined as 1) deterioration attributable to progressive ischemia, swelling of infarcted tissue or perilesional edema in patients who
were stable neurologically during 24 h or more, 2) not attributable to stroke recurrence, symptomatic hemorrhage transformation or medical illness, and 3) an
increase of total NIHSS scores 2 or more or an increase in the NIHSS subscale related to level of consciousness or motor subscale
Abbreviation: SD standard deviation, mRS modified Rankin scale, TICI Thrombolysis in Cerebral Infarction, LAA large artery atherosclerosis, CE cardiac embolism,
NIHSS National Institutes of Health Stroke Scale, IQR interquartile range, SBP systolic blood pressure, IVT intravenous thrombolysis, EVT endovascular treatment,
MCA middle cerebral artery, ICA internal carotid artery, HT hemorrhagic transformation
a Calculated by chi-squared test
b Calculated by Fisher exact test
c Calculated by Mann-Whitney U test
d Calculated by Student’s t-test
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despite a parallel increase in futile reperfusion rates,
in acute stroke patients with anterior circulation ar-
tery occlusion.
Our real-world study showed that about half (51%) of
patients treated successfully with EVT remain in a poor
functional status. Our results are similar to those of
prior studies. A multicenter EVT registry (the ENDO-
STROKE study) reported a futile reperfusion rate of 59%
[10]. Recent EVT trials reported futile reperfusion rates
(3-month mRS 3–6) ranging from 29 to 67% [4–8, 12,
17]. This persistent high proportion of futile reperfusion
mandates further research.
Our demonstration of concurrently increasing futile
reperfusion and therapeutic benefits, with increasing ini-
tial stroke severity, is novel. Because most previous EVT
trials [4–8, 12] included EVT-eligible patients with mod-
erate to severe neurological deficits only (the range of
median NIHSS scores was 15–18), an assessment of the
absolute therapeutic benefits across the full range of
initial stroke severities may not have been adequately
powered. The reproduction of the study results when
analyzing the whole EVT group rather than the successful
EVT group, and also when limiting study subjects to
those treated within 6 h of onset, demonstrates the
robustness of our findings.
Notably, our study showed the lowest benefit of EVT
in patients with the lowest NIHSS scores (NIHSS ≤5)
and a futile reperfusion rate of 21% in this NIHSS cat-
egory. The current American Heart Association guide-
lines are ambiguous regarding the role of EVT in acute
stroke patients with intracranial ICA or MCA occlusions
and initial NIHSS < 6; they state that EVT “may be rea-
sonable” when treatment can be initiated within 6 h of
onset (Class 2b, Level of Evidence B-R) [18]. As shown
in Additional file 2: Table S1, the proportion of patients
with 3-month mRS scores of 3 to 6, who had initial
NIHSS scores ≤5, was not significantly different between
the successful EVT group and the no-EVT group (20.9%
versus 24.0%, respectively; p = 0.65). Therefore, our pri-
mary study results suggest that there are no apparent
therapeutic benefits of EVT in patients with mild neuro-
logic deficits. These findings correspond to the results of
the subgroup analysis in the recent meta-analysis of the
five pivotal EVT trials [13], indicating a non-significant
OR of 1.67 (95% CI, 0.80 to 3.50) in patients with NIHSS
≤10. While the recent meta-analysis did not demonstrate
the linearity of those ORs, it should be noted that only
14 patients, out of a total of 1287 patients, were enrolled
with NIHSS ≤5 [13]. Not surprisingly, our study also
showed that clinicians typically did not initiate EVT in
mild stroke patients (Additional file 9: Table S3); only
5.6% were treated with EVT among acute ischemic pa-
tients with major anterior circulation occlusion and
NIHSS≤5. A randomized trial testing EVT is needed in
this patient population with NIHSS ≤5.
The positive associations of age and NIHSS score with
futile reperfusion are concordant with the results of earl-
ier studies [9, 10]. However, the negative association of
pre-stroke antithrombotics with futile reperfusion is not
consistent with a prior subgroup analysis of MR CLEAN
[19]. Prior studies of antithrombotics in patients treated
with intravenous (IV) thrombolysis are controversial; a
small-sized observational study reported better recanali-
zation rates and outcomes associated with pre-stroke
antithrombotics [20], whereas the recent meta-analysis
showed contradictory results [21].
Interestingly, onset to EVT start time was not associ-
ated with futile reperfusion. Previous studies suggested
that the effectiveness of EVT for acute ischemic stroke is
critically time dependent [2, 22–24]. This discrepancy
might be explained, at least in part, by the use of EVT
start time rather than reperfusion time in our study.
Fig. 1 The proportion of futile reperfusion according to NIHSS in the successful EVT group. NIHSS, National Institutes of Health Stroke Scale; EVT,
endovascular treatment
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Our study has several limitations. First, the fact that
this prospective multicenter registry database consisted
of Korean patients treated at primarily university hospi-
tals or other high-level regional stroke centers threatens
the study’s generalizability. However, the consistency of
our findings with prior studies is reassuring [11, 13].
Second, the methods of recanalization therapy (e.g., IV
thrombolysis prior to EVT and tissue plasminogen acti-
vator [tPA] dose) were heterogeneous, challenging the
study’s validity. However, adjusting for tPA dose in mul-
tivariable models did not change the results. Third, we
did not collect the Alberta Stroke Program Early Com-
puted Tomography (ASPECT) Scores [4] as well as
pre-EVT brain images, although image parameters can
be useful determinants of futile reperfusion. Forth, the
no-EVT group was used as a surrogate control group
through age-specific direct standardization in this retro-
spective analysis, and this may not sufficiently remove
baseline imbalances between those offered EVT and
those who were not (i.e., confounding by indication).
Reasons (e.g., ASPECT Score [4], perfusion imaging [6],
and DWI/perfusion mismatch [25], etc.) for not per-
forming the EVT in the no-EVT group were not available
in our registry database. Comparisons between patients
treated with EVT (the whole EVT group) and not treated
with EVT (the no-EVT group) (Additional file 10: Table
S4) suggest that delay of onset to arrival and mild neuro-
logical deficits may be partially responsible, again
Fig. 2 The predicted therapeutic benefits according to each of 4 initial NIHSS categories. The therapeutic benefits according to NIHSS of the
successful EVT group (including only TICI grade 2b to 3, a) and of the whole EVT group (regardless of reperfusion status, b) show increasing
patterns as increasing NIHSS. EVT, endovascular treatment; NIHSS, National Institutes of Health Stroke Scale
Table 2 Predictors of futile reperfusion: results of multivariable analysis
Unadjusted OR 95% CI Adjusted ORa 95% CI
Age 1.05 1.03–1.06 1.04 1.02–1.06
Male 0.66 0.45–0.97 0.67 0.43–1.05
NIHSS per 1 point 1.11 1.07–1.15 1.12 1.08–1.17
Hypertension 1.52 1.03–2.24 1.28 0.81–2.04
Diabetes Mellitus 1.41 0.90–2.22 1.10 0.61–1.96
Pre-stroke antithrombotics 0.76 0.52–1.11 0.53 0.32–0.79
Creatinine 1.42 0.85–2.38 1.11 0.60–2.07
Initial random glucose per 10 mg/dL increase 1.05 1.00–1.09 1.05 0.99–1.10
Onset to EVT start time per 10min 1.01 0.99–1.03 1.01 0.99–1.04
Preceding IVT 0.83 0.55–1.25 0.75 0.45–1.26
Abbreviation: OR odds ratio, CI confidence interval, NIHSS National Institutes of Health Stroke Scale, EVT endovascular treatment, IVT intravenous thrombolysis
a Adjusted for age, male, NIHSS, hypertension, diabetes mellitus, pre-stroke antithrombotic, creatinine, initial random glucose, onset to ET start time, preceding IVT
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implying caution regarding generalizing the study re-
sults. However, our intention was not to evaluate the ef-
fectiveness or efficacy of EVT, but to assess therapeutic
gains according to initial stroke severity by directly com-
paring patients reperfused successfully with EVT and
those who were not treated with EVT, from real-world
practice. By removing patients who failed to be reper-
fused with EVT, we tried to reduce the biases related to
selection of EVT candidates and heterogeneity of EVT
techniques. Fifth, stroke subtype was not considered in
this study, which affects stroke outcomes and might be
associated with EVT decision. We could not adjust for
stroke subtype in analysis of therapeutic benefits, like
other recent EVT trials [4, 5, 7, 8], because information
on stroke subtype is unavailable or uncertain before
EVT decision in clinical practice and its potential influ-
ence might be attenuated by stratification by NIHSS
scores. (Additional file 11: Table S5). Sixth, there were
no general protocols for EVT across the participating
centers. However, EVT was decided and performed at
the discretion of expert stroke physicians in participat-
ing centers in accordance with the ASA/AHA and
Korean stroke guidelines [18, 26, 27]. Lastly, as de-
scribed above, we were unable to obtain data regarding
onset to reperfusion times or specific EVT devices used,
and these factors could critically affect clinical outcomes.
An important thing that should be noted for this study, the
concept of “futile reperfusion” [1] is not referring to the
overall futility of treatment. For example, while more pa-
tients with older age and higher NIHSS will have poor out-
comes with reperfusion (i.e, futile reperfusion), this group
of patients will have overall better outcomes with EVT
treatment; this well established by randomized trial results.
Our findings, by showing worse outcomes in patients with
futile reperfusion, as compared to those with no reperfusion
attempted, reinforce the findings of randomized trials with
real-world data.
Conclusion
Our study suggests that both futility of EVT and thera-
peutic gains of EVT increase as stroke severity increases.
By confining this analysis to those patients who were
successfully reperfused, we provide clinicians with
considerations regarding predicted outcomes with EVT.
While individual trials and pooled analyses have already
shown the benefit of EVT in subgroups with older age
and higher NIHSS, we believe that this demonstration is
helpful for the clinician to understand the likely benefit
of EVT in real-world practice. However, despite the ro-
bustness of our findings, clinicians should be cautious in
making treatment decisions based on this retrospective
analysis alone. Our data, along with empiric evidence
from recent randomized trials, suggest that EVT is most
beneficial for acute stroke patients with moderate to
severe neurological deficits, and further study is needed
in patients with mild deficits.
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